Question 1

Which is FDA-approved for weight loss, Ozempic or Foundayo?

Accepted Answer

Only Foundayo. Ozempic is FDA-approved only for type 2 diabetes and (since 2020) for reducing major cardiovascular events in adults with T2D and established cardiovascular disease — it has no FDA weight-management indication. Foundayo (orforglipron) received FDA approval in September 2025 for chronic weight management based on ATTAIN-1 (Wharton 2025 NEJM, PMID 40960239), which showed roughly 11-12% body-weight reduction at 72 weeks. For labeled obesity treatment, Foundayo is the answer; for off-label weight loss with proven CV benefit in T2D, Ozempic remains common but is not on the label.

Question 2

Can I take Foundayo if I have type 2 diabetes?

Accepted Answer

Technically, Foundayo is labeled only for chronic weight management as of late 2025 — the T2D indication is pending based on ACHIEVE-1 (Rosenstock 2025 NEJM, PMID 40544435), which showed A1C reductions of 1.3-1.6% at 40 weeks with the 17.2 mg dose. Until that filing is approved, prescribing Foundayo for T2D is off-label and rarely covered by insurance for diabetes-only patients. If you have both obesity (BMI >=30 or >=27 + comorbidity) and T2D, Foundayo is on-label for the obesity component and will lower A1C as a clinical bonus. T2D-only patients without obesity should stay on Ozempic until the orforglipron T2D label is granted.

Question 3

Is the daily pill as effective as the weekly injection?

Accepted Answer

For A1C reduction in T2D, the molecules are roughly comparable — SUSTAIN-7 (Pratley 2018, PMID 29397376) showed Ozempic 1 mg lowered A1C by ~1.5% at 40 weeks, while ACHIEVE-1 (Rosenstock 2025) showed Foundayo 17.2 mg dropped A1C by 1.3-1.6% over the same window. For weight loss in obesity, Foundayo wins decisively: ATTAIN-1 (Wharton 2025) showed -11.1% body weight in non-diabetic obesity, whereas Ozempic in T2D trials produces only 4-7 kg loss. No head-to-head trial exists, so cross-trial gaps reflect population differences (T2D vs obesity-without-diabetes) as well as molecule differences.

Question 4

Which is cheaper without insurance?

Accepted Answer

Ozempic retails around $998/mo at U.S. pharmacies and has no manufacturer cash-pay program — NovoCare savings cards are limited to commercially insured T2D patients and exclude cash payers and Medicare/Medicaid. Foundayo's launch pricing is not yet fully public; Eli Lilly has signaled a LillyDirect direct-pay program similar to Zepbound's $349-$499/mo tier, but final maintenance pricing and insurance formulary placement may shift during 2026. For most cash payers, Foundayo is expected to be substantially cheaper than retail Ozempic once the LillyDirect tier is live.

Question 5

Why pick the pill over the injection?

Accepted Answer

Three reasons. First, needle aversion — Foundayo is a once-daily tablet, no syringe or pen required. Second, no food restriction — unlike Rybelsus (which demands an empty stomach with no more than 4 oz of plain water and a 30-minute fast), Foundayo can be taken any time of day with any meal because it is a non-peptide small molecule that survives digestion intact. Third, labeled indication — Foundayo has the obesity label Ozempic lacks, which unlocks prior authorization and (eventually) manufacturer cash-pay pricing for patients without T2D. The trade-off is losing Ozempic's SUSTAIN-6 cardiovascular outcome data.

Question 6

Which has better cardiovascular outcomes?

Accepted Answer

Ozempic, by a wide evidence margin. SUSTAIN-6 (Marso 2016 NEJM, PMID 27633186) randomized 3,297 T2D patients at high CV risk to semaglutide vs placebo and showed a 26% reduction in major adverse cardiovascular events (HR 0.74, p=0.02 for superiority) over a median 2.1 years. That trial earned Ozempic its labeled indication for CV risk reduction in adults with T2D and established CVD. Foundayo has no peer-reviewed CV outcomes trial yet — the dedicated CVOT is still being designed or enrolling, with readout likely several years out. For T2D patients with established CVD, Ozempic remains the evidence-based choice.

Field	Ozempic	Foundayo
Route & frequency	Subcutaneous injection, once weekly	Oral tablet, once daily (any time, with or without food)
Mechanism	Peptide GLP-1 receptor agonist	Non-peptide small-molecule GLP-1 receptor agonist
FDA-approved indication	Type 2 diabetes; CV risk reduction in T2D + established CVD	Chronic weight management (2025); T2D pending (ACHIEVE-1 filed)
A1C reduction (T2D)	-1.5% / 40 wk (SUSTAIN-7, 1 mg vs dulaglutide)	-1.3% to -1.6% / 40 wk (ACHIEVE-1, 17.2 mg)
Weight loss (pivotal trial)	-6.5 kg / 40 wk (SUSTAIN-7, 1 mg, T2D)	-11.1% body weight / 72 wk (ATTAIN-1, 17.2 mg, obesity)
Cardiovascular outcome	MACE -26% (SUSTAIN-6, 2016)	CV outcomes trial pending; no MACE data yet
Cash price (US, ~2026)	~$998/mo retail (no manufacturer cash-pay program)	Launching late 2025 / early 2026; LillyDirect direct-pay tier pending
Most common adverse event	Nausea (~20% at 1 mg; SUSTAIN-7)	Nausea (~20-30% dose-dependent; ATTAIN-1 / ACHIEVE-1)

Ozempic vs Foundayo (2026): Weekly Injection vs Daily Oral Pill

The verdict

Side-by-side comparison

Frequently asked questions